The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
Open accessAbstract
Disease overview: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults. Diagnosis: CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a BCR‐ABL1 fusion oncogene, which in turn translates into a BCR‐ABL oncoprotein. Frontline therapy: Four tyrosine kinase inhibitors (TKIs), imatinib, nilotinib, dasatinib, and bosutinib are approved by the United States Food and Drug Administration for first‐line treatment of newly diagnosed CML in chronic phase (CML‐CP). Clinical trials with second generation TKIs reported significantly deeper and faster responses, but they had no impact on survival prolongation, likely because of the existence of highly effective salvage therapies for patients who have a cytogenetic relapse with frontline TKI. Salvage Therapy: For CML post failure on frontline therapy, second‐line options include second and third generation TKIs. Although potent and selective, these exhibit unique pharmacological profiles and response patterns relative to different patient and disease characteristics, such as patientsʼ comorbidities, disease stage, and BCR‐ABL1 mutational status. Patients who develop the T315I “gatekeeper” mutation display resistance to all currently available TKIs except ponatinib. Allogeneic stem cell transplantation remains an important therapeutic option for patients with CML‐CP who have failed at least 2 TKIs, and for all patients in advanced phase disease. Even among older patients who have a cytogenetic relapse post failure on all TKIs, they can maintain long‐term survival if they continue on a daily most effective/less toxic TKI, with or without the addition of non‐TKI anti‐CML agents (hydroxyurea, omacetaxine, azacitidine, decitabine, cytarabine, busulfan, others).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Self-citationEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Self-citationOverriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citationNilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Saglio, G., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., Pasquini, R., Clark, R. E., Hochhaus, A., Hughes, T. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912614 · Cited by 1,678
Self-citationDasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589
Self-citationMahon, F.-X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70233-3 · Cited by 1,550
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547
Self-citationCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani, M., Deininger, M. W., Cervantes, F., Fujihara, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609324 · Cited by 1,285
Self-citationO'Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,259
Prognostic discrimination in "good-risk" chronic granulocytic leukemia
Sokal, J., Cox, E., Baccarani, M., Tura, S., Gomez, G., Robertson, J., Tso, C., Braun, T., Clarkson, B., & Cervantes, F. (1984) · Blood · doi:10.1182/blood.v63.4.789.789 · Cited by 1,214
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306494 · Cited by 1,142
Self-citationO'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036
Cortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boqué, C., Shah, N. P., Chuah, C., Casanova, L., Bradley-Garelik, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8899 · Cited by 947
Self-citationMarin, D., Bazeos, A., Mahon, F.-X., Eliasson, L., Milojkovic, D., Bua, M., Apperley, J. F., Szydlo, R., Desai, R., Kozlowski, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3087 · Cited by 909
Hasford, J., Pfirrmann, M., Hehlmann, R., Allan, N. C., Baccarani, M., Kluin-Nelemans, J. C., Alimena, G., Steegmann, J. L., & Ansari, H. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.850 · Cited by 819
Ross, D. M., Branford, S., Seymour, J. F., Schwarer, A. P., Arthur, C., Yeung, D. T., Dang, P., Goyne, J. M., Slader, C., Filshie, R. J., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483750 · Cited by 710
Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
Tokarski, J. S., Newitt, J. A., Chang, C. Y. J., Cheng, J. D., Wittekind, M., Kiefer, S. E., Kish, K., Lee, F. Y. F., Borzillerri, R., Lombardo, L. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4187 · Cited by 700
Pulmonary Arterial Hypertension in Patients Treated by Dasatinib
Montani, D., Bergot, E., Günther, S., Savale, L., Bergeron, A., Bourdin, A., Bouvaist, H., Canuet, M., Pison, C., Macro, M., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.079921 · Cited by 659
Saussele, S., Richter, J., Guilhot, J., Gruber, F. X., Hjorth-Hansen, H., Almeida, A., Janssen, J. J. W. M., Mayer, J., Koskenvesa, P., Panayiotidis, P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30192-x · Cited by 618
Noens, L., van Lierde, M.-A., De Bock, R., Verhoef, G., Zachée, P., Berneman, Z., Martiat, P., Mineur, P., Van Eygen, K., MacDonald, K., et al. (2009) · Blood · doi:10.1182/blood-2008-12-196543 · Cited by 616
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Wylie, A. A., Schoepfer, J., Jahnke, W., Cowan-Jacob, S. W., Loo, A., Furet, P., Marzinzik, A. L., Pelle, X., Donovan, J., Zhu, W., et al. (2017) · Nature · doi:10.1038/nature21702 · Cited by 614
Leukemia, E. I. C. M. (2013) · Blood · doi:10.1182/blood-2013-03-490003 · Cited by 592
Cortes, J. E., Kim, D.-W., Pinilla-Ibarz, J., le Coutre, P. D., Paquette, R., Chuah, C., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2018) · Blood · doi:10.1182/blood-2016-09-739086 · Cited by 592
Self-citationCortes, J. E., Gambacorti-Passerini, C., Deininger, M. W., Mauro, M. J., Chuah, C., Kim, D.-W., Dyagil, I., Glushko, N., Milojkovic, D., le Coutre, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7162 · Cited by 495
Ilaria, R. L., & Van Etten, R. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.49.31704 · Cited by 488
Carlesso, N., Frank, D. A., & Griffin, J. D. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.811 · Cited by 483
Marin, D., Ibrahim, A. R., Lucas, C., Gerrard, G., Wang, L., Szydlo, R. M., Clark, R. E., Apperley, J. F., Milojkovic, D., Bua, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6565 · Cited by 476
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., Breccia, M., Goh, Y.-T., Talpaz, M., Hochhaus, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902328 · Cited by 471
Silver, R. T., Woolf, S. H., Hehlmann, R., Appelbaum, F. R., Anderson, J., Bennett, C., Goldman, J. M., Guilhot, F., Kantarjian, H. M., Lichtin, A. E., et al. (1999) · PubMed · Cited by 463
Self-citationCortes, J. E., Kantarjian, H. M., Brümmendorf, T. H., Kim, D.-W., Turkina, A. G., Shen, Z.-X., Pasquini, R., Khoury, H. J., Arkin, S., Volkert, A., et al. (2011) · Blood · doi:10.1182/blood-2011-05-355594 · Cited by 463
Self-citationConstitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Shuai, K., Halpern, J., ten Hoeve, J., Rao, X., & Sawyers, C. L. (1996) · PubMed · Cited by 434
Dominant negative MYC blocks transformation by ABL oncogenes
Sawyers, C. L., Callahan, W., & Witte, O. N. (1992) · Cell · doi:10.1016/0092-8674(92)90241-4 · Cited by 397
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
Raitano, A. B., Halpern, J. R., Hambuch, T. M., & Sawyers, C. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.25.11746 · Cited by 394
Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
Preudhomme, C., Guilhot, J., Nicolini, F. E., Guerci-Bresler, A., Rigal-Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004095 · Cited by 392
Hehlmann, R., Lauseker, M., Jung-Munkwitz, S., Leitner, A., Müller, M. C., Pletsch, N., Proetel, U., Haferlach, C., Schlegelberger, B., Balleisen, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.0598 · Cited by 323
Schoch, C., Schnittger, S., Bursch, S., Gerstner, D., Hochhaus, A., Berger, U., Hehlmann, R., Hiddemann, W., & Haferlach, T. (2002) · Leukemia · doi:10.1038/sj.leu.2402329 · Cited by 314
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Holyoake, T. L., & Vetrie, D. (2017) · Blood · doi:10.1182/blood-2016-09-696013 · Cited by 314
Hughes, T., Saglio, G., Branford, S., Soverini, S., Kim, D.-W., Müller, M. C., Martinelli, G., Cortes, J., Beppu, L., Gottardi, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.8230 · Cited by 306
Huang, X., Cortes, J., & Kantarjian, H. (2012) · Cancer · doi:10.1002/cncr.26679 · Cited by 300
Self-citationCortes, J., Jabbour, E., Kantarjian, H., Yin, C. C., Shan, J., O'Brien, S., Garcia-Manero, G., Giles, F., Breeden, M., Reeves, N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080838 · Cited by 296
Self-citationHochhaus, A., Masszi, T., Giles, F. J., Radich, J. P., Ross, D. M., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., García-Gutiérrez, V, et al. (2017) · Leukemia · doi:10.1038/leu.2017.63 · Cited by 293
Müller, M. C., Cortes, J. E., Kim, D.-W., Druker, B. J., Erben, P., Pasquini, R., Branford, S., Hughes, T. P., Radich, J. P., Ploughman, L., et al. (2009) · Blood · doi:10.1182/blood-2009-04-214221 · Cited by 290
Zhou, T., Commodore, L., Huang, W., Wang, Y., Thomas, M., Keats, J., Xu, Q., Rivera, V. M., Shakespeare, W. C., Clackson, T., et al. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.01054.x · Cited by 287
Cortes, J. E., Baccarani, M., Guilhot, F., Druker, B. J., Branford, S., Kim, D.-W., Pane, F., Pasquini, R., Goldberg, S. L., Kalaycio, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3724 · Cited by 284
Self-citationDarkow, T., Henk, H. J., Thomas, S. K., Feng, W., Baladi, J.-F., Goldberg, G. A., Hatfield, A., & Cortes, J. (2007) · PharmacoEconomics · doi:10.2165/00019053-200725060-00004 · Cited by 271
Carpenter, P. A., Snyder, D., Flowers, M. E. D., Sanders, J. E., Gooley, T. A., Martin, P. J., Appelbaum, F. R., & Radich, J. P. (2006) · Blood · doi:10.1182/blood-2006-04-019836 · Cited by 226
Kantarjian, H., Pasquini, R., Lévy, V., Jootar, S., Holowiecki, J., Hamerschlak, N., Hughes, T., Bleickardt, E., Dejardin, D., Cortes, J., et al. (2009) · Cancer · doi:10.1002/cncr.24504 · Cited by 215
Self-citationTyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia
Quintás-Cardama, A., Han, X., Kantarjian, H., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2008-09-180604 · Cited by 207
Self-citationWang, W., Cortes, J. E., Tang, G., Khoury, J. D., Wang, S., Bueso-Ramos, C. E., DiGiuseppe, J. A., Chen, Z., Kantarjian, H. M., Medeiros, L. J., et al. (2016) · Blood · doi:10.1182/blood-2016-01-690230 · Cited by 198
Self-citationSimonsson, B., Gedde-Dahl, T., Markevärn, B., Remes, K., Stentoft, J., Almqvist, A., Björeman, M., Flogegård, M., Koskenvesa, P., Lindblom, A., et al. (2011) · Blood · doi:10.1182/blood-2011-02-336685 · Cited by 194
Apperley, J. F., Cortes, J. E., Kim, D.-W., Roy, L., Roboz, G. J., Rosti, G., Bullorsky, E. O., Abruzzese, E., Hochhaus, A., Heim, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3339 · Cited by 194
Shah, N. P., Rousselot, P., Schiffer, C., Rea, D., Cortes, J. E., Milone, J., Mohamed, H., Healey, D., Kantarjian, H., Hochhaus, A., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24423 · Cited by 181
Self-citationRadich, J. P., Kopecky, K. J., Appelbaum, F. R., Kamel-Reid, S., Stock, W., Malnassy, G., Paietta, E., Wadleigh, M., Larson, R. A., Emanuel, P., et al. (2012) · Blood · doi:10.1182/blood-2012-02-410688 · Cited by 174
Chamoun, K., Kantarjian, H., Atallah, R., Gonzalez, G. N., Issa, G. C., Rios, M. B., Garcia-Manero, G., Borthakur, G., Ravandi, F., Jain, N., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0686-1 · Cited by 174
Self-citationCarter, B. Z., Mak, P. Y., Mu, H., Zhou, H., Mak, D. H., Schober, W., Leverson, J. D., Zhang, B., Bhatia, R., Huang, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag1180 · Cited by 170
Self-citationRole of p21 RAS in p210 bcr-abl transformation of murine myeloid cells
Mandanas, R., Leibowitz, D., Gharehbaghi, K., Tauchi, T., Burgess, G., Miyazawa, K., Jayaram, H., & Boswell, H. (1993) · Blood · doi:10.1182/blood.v82.6.1838.1838 · Cited by 165
Jain, P., Kantarjian, H. M., Ghorab, A., Sasaki, K., Jabbour, E. J., Nogueras Gonzalez, G., Kanagal‐Shamanna, R., Issa, G. C., Garcia‐Manero, G., KC, D., et al. (2017) · Cancer · doi:10.1002/cncr.30864 · Cited by 160
Self-citationKantarjian, H., Schiffer, C., Jones, D., & Cortes, J. (2008) · Blood · doi:10.1182/blood-2007-09-110189 · Cited by 158
Self-citationGallipoli, P., Cook, A., Rhodes, S., Hopcroft, L., Wheadon, H., Whetton, A. D., Jørgensen, H. G., Bhatia, R., & Holyoake, T. L. (2014) · Blood · doi:10.1182/blood-2013-12-545640 · Cited by 158
Jabbour, E. J., Kantarjian, H. M., Jones, D. M., Shan, J., O'Brien, S. M., Reddy, N., Wierda, W. G., Faderl, S. H., Garcia‐Manero, G., Verstovšek, S., et al. (2008) · Blood · doi:10.1182/blood-2008-04-154344 · Cited by 155
Self-citationKantarjian, H. M., Cortes, J. E., Kim, D., Khoury, H. J., Brümmendorf, T. H., Porkka, K., Martinelli, G., Durrant, S., Leip, E. P., Kelly, V. M., et al. (2013) · Blood · doi:10.1182/blood-2013-07-513937 · Cited by 151
Self-citationPunish the parent not the progeny
Elrick, L. J., Jørgensen, H. G., Mountford, J. C., & Holyoake, T. L. (2004) · Blood · doi:10.1182/blood-2004-08-3373 · Cited by 148
Ross, D. M., Masszi, T., Gómez‐Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., García‐Gutiérrez, V., Gattermann, N., le Coutre, P. D., Martino, B., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2604-x · Cited by 147
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy
Quintás‐Cardama, A., Kantarjian, H. M., Ravandi, F., O'Brien, S. M., Thomas, D. M., Vidal‐Senmache, G., Wierda, W. G., Kornblau, S. M., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24257 · Cited by 144
Self-citationNaqvi, K., Jabbour, E., Skinner, J., Anderson, K., Dellasala, S., Yilmaz, M., Ferrajoli, A., Bose, P., Thompson, P., Alvarado, Y., et al. (2020) · Cancer · doi:10.1002/cncr.32504 · Cited by 135
Self-citationJain, P., Kantarjian, H. M., Nazha, A., O'Brien, S. M., Jabbour, E. J., Romo, C. G., Pierce, S. A., Cárdenas-Turanzas, M., Verstovšek, S., Borthakur, G. M., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490128 · Cited by 134
Self-citationLee, S. J., Kukreja, M. K., Wang, T., Giralt, S. A., Szer, J., Arora, M., Woolfrey, A. E., Cervantes, F., Champlin, R. E., Gale, R. P., et al. (2008) · Blood · doi:10.1182/blood-2008-02-141689 · Cited by 133
Oehler, V. G., Gooley, T. A., Snyder, D., Johnston, L., Lin, A., Cummings, C. C., Chu, S., Bhatia, R., Forman, S. J., Negrin, R. S., et al. (2006) · Blood · doi:10.1182/blood-2006-06-031682 · Cited by 132
Nicolini, F. E., Basak, G. W., Kim, D., Olavarría, E., Pinilla-Ibarz, J. A., Apperley, J. F., Hughes, T. P., Niederwieser, D. W., Mauro, M. J., Chuah, C. T. H., et al. (2017) · Cancer · doi:10.1002/cncr.30558 · Cited by 120
Self-citationWhy Are Cancer Drugs So Expensive in the United States, and What Are the Solutions?
Kantarjian, H. M., & Rajkumar, S. V. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.01.014 · Cited by 115
Self-citationWang, J., Shen, Z., Saglio, G. N., Jin, J., Huang, H., Hu, Y., Du, X., Li, J., Meng, F., Zhu, H., et al. (2015) · Blood · doi:10.1182/blood-2014-09-601674 · Cited by 113
Schnekenburger, M., Grandjenette, C., Ghelfi, J., Karius, T., Foliguet, B., Dicato, M. A., & Diederich, M. F. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.10.013 · Cited by 107
le Coutre, P. D., Giles, F. J., Hochhaus, A., Apperley, J. F., Ossenkoppele, G. J., Blakesley, R. E., Shou, Y., Gallagher, N. J., Baccarani, M., Cortes, J. E., et al. (2011) · Leukemia · doi:10.1038/leu.2011.323 · Cited by 99
Self-citationNeelakantan, P., Gerrard, G., Lucas, C., Milojković, D., May, P. C., Wang, L., Paliompeis, C., Bua, M., Reid, A. G., Rezvani, K., et al. (2013) · Blood · doi:10.1182/blood-2012-11-466037 · Cited by 95
Jain, P., Kantarjian, H. M., Alattar, M. L., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00021-6 · Cited by 83
Self-citationJabbour, E. J., Branford, S., Saglio, G. N., Jones, D. M., Cortes, J. E., & Kantarjian, H. M. (2010) · Cancer · doi:10.1002/cncr.25717 · Cited by 82
Self-citationTestoni, N., Marzocchi, G., Luatti, S., Amabile, M., Baldazzi, C., Stacchini, M., Nanni, M., Rege‐Cambrin, G., Giugliano, E., Giussani, U., et al. (2009) · Blood · doi:10.1182/blood-2009-07-229864 · Cited by 81
Jabbour, E. J., Kantarjian, H. M., O'Brien, S. M., Shan, J., Quintás‐Cardama, A., Garcia‐Manero, G., Rios, M. B., & Cortes, J. E. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0693 · Cited by 78
Self-citationNaqvi, K., Jabbour, E. J., Skinner, J. A., Yilmaz, M. E., Ferrajoli, A., Bose, P., Thompson, P. A., Alvarado, Y., Jain, N., Takahashi, K., et al. (2018) · Cancer · doi:10.1002/cncr.31357 · Cited by 77
Self-citationJabbour, E. J., Cortes, J. E., Santos, F. P. D. S., Jones, D. M., O'Brien, S. M., Rondón, G., Popat, U., Giralt, S. A., Kebriaei, P., Jones, R. B., et al. (2010) · Blood · doi:10.1182/blood-2010-08-302679 · Cited by 76
Self-citationHjorth‐Hansen, H., Stentoft, J., Richter, J., Koskenvesa, P., Höglund, M., Dreimane, A., Porkka, K., Gedde‐Dahl, T., Gjertsen, B. T., Gruber, F., et al. (2016) · Leukemia · doi:10.1038/leu.2016.121 · Cited by 72
Ko, T. K., Chuah, C. T. H., Huang, J. W. J., Ng, K.-P., & Ong, S. T. (2014) · Oncotarget · doi:10.18632/oncotarget.1925 · Cited by 71
Kantarjian, H. M., Shan, J., Jones, D. M., O'Brien, S. M., Rios, M. B., Jabbour, E. J., & Cortes, J. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.6999 · Cited by 68
Self-citationHCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia
Strati, P., Kantarjian, H. M., Thomas, D. A., O'Brien, S. M., Konoplev, S. N., Jorgensen, J. L., Luthra, R., Abruzzo, L. V., Jabbour, E. J., Quintás‐Cardama, A., et al. (2013) · Cancer · doi:10.1002/cncr.28433 · Cited by 66
Self-citationChronic myeloid leukemia: First‐line drug of choice
Jabbour, E. J. (2015) · American Journal of Hematology · doi:10.1002/ajh.24249 · Cited by 65
Self-citationJabbour, E. J., Cortes, J. E., Kantarjian, H. M., Giralt, S., Andersson, B. S., Giles, F. J., Shpall, E. J., Kebriaei, P., Champlin, R. E., & de Lima, M. (2007) · Cancer · doi:10.1002/cncr.22778 · Cited by 64
Self-citationQuintás‐Cardama, A., Cortes, J. E., O'Brien, S. M., Ravandi, F., Borthakur, G. M., Liu, D., Bleickardt, E. W., Chen, T., & Kantarjian, H. M. (2009) · Cancer · doi:10.1002/cncr.24325 · Cited by 62
Self-citationMolecular monitoring in chronic myeloid leukemia
Jabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2008) · Cancer · doi:10.1002/cncr.23427 · Cited by 59
Self-citationShih, Y. T., Cortes, J. E., & Kantarjian, H. M. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30087-0 · Cited by 58
Self-citationOhanian, M. N., Kantarjian, H. M., Quintás‐Cardama, A., Jabbour, E. J., Abruzzo, L. V., Verstovšek, S., Borthakur, G. M., Ravandi, F., Garcia‐Manero, G., Champlin, R. E., et al. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.08.008 · Cited by 56
Self-citationCortes, J. E., Gambacorti-Passerini, C. B., Kim, D., Kantarjian, H. M., Lipton, J. H., Lahoti, A., Talpaz, M., Matczak, E. M., Barry, E. V., Leip, E. P., et al. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.06.001 · Cited by 54
Self-citationMarin, D., Ibrahim, A., Lucas, C., Gerrard, G., Wang, L., Szydlo, R., Clark, R., Apperley, J., Milojkovic, D., Bua, M., et al. (2012) · UCL Discovery (University College London) · Cited by 50
Hughes, T. P., Leber, B. F., Cervantes, F., Spector, N., Pasqüini, R., Clementino, N., Schwarer, A. P., Dorlhiac‐Llacer, P. E., Mahon, F., Réa, D., et al. (2017) · Leukemia · doi:10.1038/leu.2017.247 · Cited by 44
Cortes, J. E., Souza, C. A. D., Ayala, M., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30167-3 · Cited by 42
Kantarjian, H. M., & Cortes, J. E. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9176 · Cited by 40
Self-citationThe Chronic Myeloid Leukemia Stem Cell
Nicholson, E., & Holyoake, T. L. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.s.037 · Cited by 38
Yamamoto, C., Nakashima, H., Ikeda, T., Kawaguchi, S., Toda, Y., Ito, S., Mashima, K., Nagayama, T., Umino, K., Minakata, D., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000745 · Cited by 38
Nazha, A., Kantarjian, H. M., Jain, P., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.090282 · Cited by 35
Self-citationLong‐term results of frontline dasatinib in chronic myeloid leukemia
Maiti, A., Cortes, J. E., Patel, K. P., Masárová, L., Borthakur, G. M., Ravandi, F., Verstovšek, S., Ferrajoli, A., Estrov, Z. E., Garcia‐Manero, G., et al. (2020) · Cancer · doi:10.1002/cncr.32627 · Cited by 34
Self-citationHigh cancer drug prices 4 years later—Progress and prospects
Kantarjian, H. M., & Patel, Y. B. (2017) · Cancer · doi:10.1002/cncr.30545 · Cited by 32
Self-citationSudden blastic transformation in treatment‐free remission chronic myeloid leukaemia
Alfayez, M., Richard‐Carpentier, G., Jabbour, E. J., Vishnu, P., Naqvi, K., Sasaki, K., Cortes, J. E., & Pemmaraju, N. (2019) · British Journal of Haematology · doi:10.1111/bjh.16245 · Cited by 31
Self-citationHughes, T. P., Saglio, G. N., Larson, R. A., Kantarjian, H. M., Kim, D.-W., Issaragrisil, S., le Coutre, P., Étienne, G., Boquimpani, C. M., Clark, R. E., et al. (2019) · Blood · doi:10.1182/blood-2019-128761 · Cited by 29
Self-citationO’Brien, S. G., Hedgley, C. A., Adams, S., Foroni, L., Apperley, J. F., Holyoake, T. L., Pocock, C., Byrne, J., Seeley, L. M., Osborne, W., et al. (2014) · Blood · doi:10.1182/blood.v124.21.517.517 · Cited by 26
Jabbour, E. J., Kantarjian, H. M., Ghanem, H., O'Brien, S. M., Quintás‐Cardama, A., Garcia‐Manero, G., Cardenas, M., & Cortes, J. E. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.12.005 · Cited by 23
Self-citationCortes, J. E., Hochhaus, A., Kantarjian, H. M., Guilhot, F., Kota, V. K., Hughes, T. P., Shelat, S. G., Li, L., & Jabbour, E. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.7051 · Cited by 23
Self-citationCopland, M., Slade, D., Byrne, J., Brock, K., de Lavallade, H., Craddock, C., Clark, R. E., Smith, M., Bishop, R., Milojković, D., et al. (2019) · Blood · doi:10.1182/blood-2019-125591 · Cited by 21
Masárová, L., Cortes, J. E., Patel, K. P., O'Brien, S. M., Nogueras‐González, G. M., Konopleva, M. Y., Verstovšek, S., Garcia‐Manero, G., Ferrajoli, A., Kadia, T. M., et al. (2020) · Cancer · doi:10.1002/cncr.32623 · Cited by 20
Self-citationHochhaus, A., Burchert, A., Saußele, S., Baerlocher, G. M., Brümmendorf, T. H., Rosée, P. G. L., Heim, D. A., Krause, S. W., le Coutre, P. D., Niederwieser, D. W., et al. (2019) · Blood · doi:10.1182/blood-2019-130043 · Cited by 14
Hjorth‐Hansen, H., Stentoft, J., Richter, J., Koskenvesa, P., Dreimane, A., Porkka, K., Gedde‐Dahl, T., Gjertsen, B. T., Gruber, F., Höglund, M., et al. (2015) · Blood · doi:10.1182/blood.v126.23.477.477 · Cited by 13
Rousselot, P. H., Loiseau, C., Delord, M., Besson, C., Cayuela, J., & Spentchian, M. (2019) · Blood · doi:10.1182/blood-2019-129919 · Cited by 9
Monitoring and defining early response: Where to draw the line?
Branford, S. (2016) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2016.10.006 · Cited by 6
Cited by
Trends in kinase drug discovery: targets, indications and inhibitor design
Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 779
Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
Survival with chronic myeloid leukaemia after failing milestones
Lauseker, M., Hehlmann, R., Hochhaus, A., & Saußele, S. (2023) · Leukemia · doi:10.1038/s41375-023-02028-2 · Cited by 38
Metadata
- Authors
- Jabbour, E., & Kantarjian, H.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2020-04-10
- Volume
- 95
- Issue
- 6
- Pages
- 691-709
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W3014892303
- Cited by
- 410
- References
- 116
- FWCI
- 31.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.